Yang, Yaqiong <br/><br/>
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.  [electronic resource] 

 -  Neoplasia (New York, N.Y.)  Jun 2012 
 - 509-18 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5586 
<br/><br/><label>Standard No.: </label>10.1593/neo.12328  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>Benzenesulfonates--administration & dosage<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm--genetics<br/>Drug Synergism<br/>ErbB Receptors--antagonists & inhibitors<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Liver Neoplasms--genetics<br/>MAP Kinase Signaling System--drug effects<br/>Mice<br/>Mice, Nude<br/>Neovascularization, Pathologic--drug therapy<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Pyridines--administration & dosage<br/>STAT3 Transcription Factor--metabolism<br/>Sorafenib<br/>Xenograft Model Antitumor Assays